Mobile

SPC2996 in Chronic Lymphocytic Leukaemia An open-labelled, international multicenter dose escalating, phase I/II study of SPC2996, an LNA antisense molecule against Bcl-2, in patients with relapsed or...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-004741-17

SPC2996 in Chronic Lymphocytic Leukaemia An open-labelled, international multicenter dose escalating, phase I/II study of SPC2996, an LNA antisense molecule against Bcl-2, in patients with relapsed or refractory Chronic Lymphocytic Leukaemia

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To investigate the safety and efficacy of SPC2996 in CLL patients

Critère d'inclusion

  • Chronic Lymphocytic Leukaemia (CLL) is the most common leukaemia in adults in the US and most of Western Europe. The incidence is 8100 to 12500 new cases in the US per year. CLL is a relatively indolent disease mainly of the elderly. CLL is a disease of B cell origin grouped together with small lymphocytic lymphoma (SLL) in the WHO classification system. CLL and SLL together correspond to around 20 % of all NHL cases

Liens